CBU
IOVA icon

CIBC Bancorp USA’s Iovance Biotherapeutics IOVA Stock Holding History

CIBC Bancorp USA’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$91.7K Buy
22,044
+5,056
+30% +$19.2K ﹤0.01% 1861
2026
Q1 		$59.6K Buy
+16,988
New +$54.3K ﹤0.01% 1712
2025
Q3 		$60.4K Buy
+27,834
New +$65.7K ﹤0.01% 1402

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

CIBC Bancorp USA's IOVA Position: Q2 2026 in Review

CIBC Bancorp USA increased its Iovance Biotherapeutics (IOVA) stake by 30% in Q2 2026, buying an estimated $19.2K and bringing the position to 22,044 shares worth $91.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1861.

CIBC Bancorp USA first reported a position in IOVA in Q3 2025 and has held it in 3 quarters since. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • CIBC Bancorp USA held 22,044 shares of Iovance Biotherapeutics worth $91.7K as of Q2 2026.
  • CIBC Bancorp USA bought 5,056 Iovance Biotherapeutics shares in Q2 2026, an estimated $19.2K.
  • Iovance Biotherapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q2 2026, its #1861 holding.
  • CIBC Bancorp USA first reported a position in Iovance Biotherapeutics in Q3 2025 and has held it in 3 quarters since.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.